Arvinas doses first patient in Phase 1/2 trial of HPK1 degrader ARV-6723 in advanced solid tumors

By Public Technologies
  • Arvinas dosed the first patient in a Phase 1/2 trial of ARV-6723 for advanced solid tumors.
  • No clinical results have been presented; the study will generate initial safety, drug-behavior, and early antitumor readouts.
  • Program expands Arvinas into immuno-oncology with an oral PROTAC designed to remove HPK1, a brake on immune activation.
  • Trial tests ARV-6723 alone, then with pembrolizumab, targeting patients previously treated with checkpoint inhibitors lacking standard options.
  • Preclinical work showed immune activation and tumor-control signals, including in models resistant to anti-PD-1 therapy.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arvinas Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609280700PRIMZONEFULLFEED9834349) on September 28, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.